Evaluation of the efficacy of a modified-live combination vaccine against bovine viral diarrhea virus types 1 and 2 challenge exposures in a one-year duration-of-immunity fetal protection study.
This study demonstrated that the modified-live bovine viral diarrhea virus (BVDV) type 1 and 2 fractions of a multivalent vaccine protected pregnant heifers and their fetuses against virulent BVDV types 1 and 2 challenge exposures at 370 days after vaccination. All BVDV vaccinated heifers inoculated with either BVDV type 1 or 2 at approximately 62 to 94 days of gestation delivered fetuses or calves that were negative for BVDV by ear-notch immunohistochemistry and virus isolation and serum neutralization on a prenursing serum sample. In comparison, eight of nine and 10 of 10 fetuses or calves from non-BVDV-vaccinated heifers were considered persistently infected following exposure to BVDV type 1 and type 2, respectively.
Ficken
Martin D
MD
Benchmark BioLabs, Inc., 421 West Industrial Lake Drive, Lincoln, Nebraska 68528, USA.
Ellsworth
Michael A
MA
Tucker
Cassius M
CM
D000034:Abortion, Veterinary / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000517:prevention & control*; D002417:Cattle; D030241:Diarrhea Virus 1, Bovine Viral / Q000276:immunology*; D030242:Diarrhea Virus 2, Bovine Viral / Q000276:immunology*; D005260:Female; D007150:Immunohistochemistry / Q000662:veterinary; D011247:Pregnancy; D013997:Time Factors; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D014765:Viral Vaccines